Jerome Martinez

Neurophoenix is a preclinical stage biotech company advancing its rabies virus biomimicry based PTEN inactivation compounds to unlock neuron repair in optic neuropathies (NAION, glaucoma) and several other neuronal diseases.

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

MDoloris Medical Systems is a young innovative start-up (ISO 9001 and ISO 13485 certified) created in June 2010 to leverage more than 23 years of academic research conducted at the University Hospital of Lille. Our mission is to provide clinicians with the means to efficiently, continuously and non-invasively asses patient pain and comfort. The goal is to personalize pain therapy, in order to avoid known adverse effects of over- or underdosage of those drugs. Our technology is ideal when patients are unable to communicate, such as when they are under general anesthesia or unconscious in intensive care units, and also in children and newborn infants, dementia and Alzheimer's patients, and more. ------------------------------------------------------------------------------------------------------------------------------------------- Valorisant plus de 23 années de recherche académique, réalisées au sein du CHRU de Lille, Mdoloris Medical Systems est une jeune start-up (certifiée ISO 9001 et ISO 13485) innovante crée en Juin 2010. Notre mission consiste à fournir aux cliniciens des technologies permettant une évaluation fiable, continue et non-invasive de la douleur et du confort de leurs patients. L'objectif consiste à personnaliser la thérapeutique antidouleur afin d’éviter les effets indésirables des sur ou sous dosages de ces drogues. Nos technologies prennent tout leur sens lorsque les patients sont dans l’incapacité d’exprimer le ressenti douloureux (sous anesthésie générale, patients inconscients en réanimation, mais également les enfants, les patients atteints de démence, Alzheimer etc…).

Neurophoenix is a preclinical stage biotech company advancing its rabies virus biomimicry based PTEN inactivation compounds to unlock neuron repair in optic neuropathies (NAION, glaucoma) and several other neuronal diseases.

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

MDoloris Medical Systems is a young innovative start-up (ISO 9001 and ISO 13485 certified) created in June 2010 to leverage more than 23 years of academic research conducted at the University Hospital of Lille. Our mission is to provide clinicians with the means to efficiently, continuously and non-invasively asses patient pain and comfort. The goal is to personalize pain therapy, in order to avoid known adverse effects of over- or underdosage of those drugs. Our technology is ideal when patients are unable to communicate, such as when they are under general anesthesia or unconscious in intensive care units, and also in children and newborn infants, dementia and Alzheimer's patients, and more. ------------------------------------------------------------------------------------------------------------------------------------------- Valorisant plus de 23 années de recherche académique, réalisées au sein du CHRU de Lille, Mdoloris Medical Systems est une jeune start-up (certifiée ISO 9001 et ISO 13485) innovante crée en Juin 2010. Notre mission consiste à fournir aux cliniciens des technologies permettant une évaluation fiable, continue et non-invasive de la douleur et du confort de leurs patients. L'objectif consiste à personnaliser la thérapeutique antidouleur afin d’éviter les effets indésirables des sur ou sous dosages de ces drogues. Nos technologies prennent tout leur sens lorsque les patients sont dans l’incapacité d’exprimer le ressenti douloureux (sous anesthésie générale, patients inconscients en réanimation, mais également les enfants, les patients atteints de démence, Alzheimer etc…).